Fig. 7: Clinical application of MAOSS and comparison to standard of care Referral (to GI/Hepatology Specialists) Pathways. | Nature Communications

Fig. 7: Clinical application of MAOSS and comparison to standard of care Referral (to GI/Hepatology Specialists) Pathways.

From: Multi-modal AI for opportunistic screening, staging and progression risk stratification of steatotic liver disease

Fig. 7: Clinical application of MAOSS and comparison to standard of care Referral (to GI/Hepatology Specialists) Pathways.

a Current AASLD clinical workflow41 for screening steatotic liver disease patients who are at risk of progression (AASLD pathway), with MAOSS embedded (MAOSS pathway). b SLD patients stratified into low, intermediate and high risk with AASLD/MAOSS pathway. c Comparison AASLD and MAOSS pathway for identifying SLD patients at risk of fibrosis progression. Competing risks analysis shows the cumulative incidence of a subgroup of patients (n = 236) who developed cirrhosis at the end (n = 39). Kaplan Meier plots. d Show stratification of patients according to the AASLD pathway. e show stratification of patients according to the MAOSS pathway. Shaded areas represent 95% CIs for the cumulative incidence curves. Gray’s test was used to assess differences in rates of cirrhosis incidence between groups. Two-sided p value less than 0.05 was considered statistically significant. Source data are provided as a Source Data file. Created in BioRender. Li, c. (2025) https://BioRender.com/ohxalky.

Back to article page